TELEBRIX 38 ORAL 255 MG
SODIUM IOXITALAMATE : 255 MG MEGLUMINE IOXITALAMATE : 513 MG · DIN 02131684 · LIEBEL-FLARSHEIM CANADA INC
Health Canada status: CANCELLED POST MARKET
What is TELEBRIX 38 ORAL?
TELEBRIX 38 ORAL 255 MG contains SODIUM IOXITALAMATE : 255 MG MEGLUMINE IOXITALAMATE : 513 MG. It is listed in the Health Canada Drug Product Database under DIN 02131684, held by LIEBEL-FLARSHEIM CANADA INC, supplied as SOLUTION for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 07-Aug-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TELEBRIX 38 ORAL used for?
Bowel opacifier during CT scanning of the abdomen and pelvis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02131684 |
|---|---|
| Brand name | TELEBRIX 38 ORAL |
| Generic / active ingredient | SODIUM IOXITALAMATE : 255 MG MEGLUMINE IOXITALAMATE : 513 MG |
| Manufacturer | LIEBEL-FLARSHEIM CANADA INC |
| Strength | 255 MG |
| Dosage form | SOLUTION |
| Route of administration | ORAL |
| Schedule | Ethical |
| ATC code | V08AA05 IOXITALAMIC ACID |
| AHFS class | 36:68.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 07-Aug-2020 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Must be diluted to 2% w/v (e.g., 12 mL in 450 mL water). Adults: 450-1050 mL total depending on organ. Children 1-12: max 8 mL/kg or 400 mL total. Administered in small aliquots over time.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15°C to 30°C. Do not freeze. Protect from light. Diluted solution stable for 2 weeks at room temperature, but 48 hours recommended.
How is it supplied?
Available in 30 mL and 120 mL bottles.
Contraindications
Hypersensitivity to ioxitalamate acid salts; severe oliguria or anuria; history of major skin reactions; suspected broncho-esophageal fistula or aspiration risk; manifest thyrotoxicosis.
Warnings and precautions
Do not inject. Risk of life-threatening hypersensitivity/anaphylaxis. Increased absorption if GI mucosa is altered. May induce thyroid dysfunction. Ensure resuscitation equipment is available.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.